Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.Eur. Heart J. 2021; 42: 3227-3337
- Relationship between diabetes and ischaemic injury among patients with revascularized ST-elevation myocardial infarction.Diabetes Obes. Metab. 2017; 19: 1706-1713
- Relation of low-density lipoprotein cholesterol with microvascular injury and clinical outcome in revascularized ST-elevation myocardial infarction.J. Am. Heart Assoc. 2017; 6
- Obesity paradox in ST-elevation myocardial infarction: is it all about infarct size?.Eur. Hear J. Qual. Care Clin. Outcomes. 2018; 5: 180-182
- Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.Lancet. 2021; 397: 1085-1094
- ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors-how common are they, and what are their outcomes?.J. Am. Heart Assoc. 2019; 8e013296
- Coronary artery disease in the absence of traditional risk factors: a call for action.Eur. Heart J. 2021; 42: 3822-3824
- Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: results from a global meta-analysis of 1,285,722 patients.Int. J. Cardiol. 2022; 27 (S0167-5273(22)01413-9, Online ahead of print)https://doi.org/10.1016/j.ijcard.2022.09.062
- Clinical outcomes in patients with ST-segment elevation MI and no standard modifiable cardiovascular risk factors.JACC Cardiovasc. Interv. 2022; 15: 1167-1175